adenine has been researched along with Liver Dysfunction in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy." | 7.74 | Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008) |
| "Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate." | 6.42 | [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]. ( Cho, YK; Kim, BI, 2003) |
| "We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy." | 3.74 | Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008) |
| "As expected for a renally eliminated drug, subjects with and without hepatic impairment displayed similar tenofovir systemic exposures without evidence of substantial alterations in drug disposition, and therefore no dosage adjustments were warranted in these patients." | 2.72 | Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. ( Flaherty, JF; Kearney, BP; Shah, J; Yale, K; Zhong, L, 2006) |
| "Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent." | 2.48 | Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012) |
| " This drug is administered orally in the form of disoproxil ester, which is deesterified to achieve a bioavailability of more than 20%." | 2.44 | [Tenofovir: pharmacology and interactions]. ( Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B, 2008) |
| "Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate." | 2.42 | [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]. ( Cho, YK; Kim, BI, 2003) |
| "Similar to ADPKD, Pkd1 cKO mice developed renal and hepatic cysts." | 1.38 | CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. ( Bukanov, NO; Galons, H; Ibraghimov-Beskrovnaya, O; Ledbetter, SR; Meijer, L; Moreno, SE; Natoli, TA; Oumata, N; Rogers, KA; Smith, LA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (24.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Q | 1 |
| Luo, J | 1 |
| Xiong, Y | 1 |
| Liu, Z | 1 |
| Ye, Q | 1 |
| Kim, Y | 1 |
| Hong, SA | 1 |
| Yu, J | 1 |
| Eom, J | 1 |
| Jang, K | 1 |
| Yoon, S | 1 |
| Hong, DH | 1 |
| Seo, D | 1 |
| Lee, SN | 1 |
| Woo, JS | 1 |
| Jeong, J | 1 |
| Bae, S | 1 |
| Choi, D | 1 |
| Sun, H | 1 |
| Lv, J | 1 |
| Tu, Z | 1 |
| Hu, X | 1 |
| Yan, H | 1 |
| Pan, Y | 1 |
| Xu, D | 1 |
| Lian, Z | 1 |
| Chi, X | 1 |
| Niu, J | 1 |
| de Vries, R | 2 |
| Huang, M | 1 |
| Bode, N | 1 |
| Jejurkar, P | 1 |
| Jong, Jd | 1 |
| Sukbuntherng, J | 2 |
| Sips, L | 1 |
| Weng, N | 1 |
| Timmerman, P | 1 |
| Verhaeghe, T | 1 |
| Zhou, H | 1 |
| Zhu, J | 1 |
| Yue, S | 1 |
| Lu, L | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Wang, X | 1 |
| Zhai, Y | 1 |
| de Jong, J | 1 |
| Skee, D | 1 |
| Hellemans, P | 1 |
| Jiao, J | 1 |
| Swerts, D | 1 |
| Lawitz, E | 1 |
| Marbury, T | 1 |
| Smith, W | 1 |
| Mannaert, E | 1 |
| Azanza, JR | 1 |
| García Quetglas, E | 1 |
| Sádaba, B | 1 |
| Gómez-Giu, A | 1 |
| Mallolas, J | 1 |
| Ribera Pascuet, E | 1 |
| Curran, A | 1 |
| Imaizumi, T | 1 |
| Higaki, Y | 1 |
| Hara, M | 1 |
| Sakamoto, T | 1 |
| Horita, M | 1 |
| Mizuta, T | 1 |
| Eguchi, Y | 1 |
| Yasutake, T | 1 |
| Ozaki, I | 1 |
| Yamamoto, K | 1 |
| Onohara, S | 1 |
| Kawazoe, S | 1 |
| Shigematsu, H | 1 |
| Koizumi, S | 1 |
| Kudo, S | 1 |
| Tanaka, K | 1 |
| Naggie, S | 1 |
| Sulkowski, MS | 1 |
| Bukanov, NO | 1 |
| Moreno, SE | 1 |
| Natoli, TA | 1 |
| Rogers, KA | 1 |
| Smith, LA | 1 |
| Ledbetter, SR | 1 |
| Oumata, N | 1 |
| Galons, H | 1 |
| Meijer, L | 1 |
| Ibraghimov-Beskrovnaya, O | 1 |
| BECKMANN, K | 1 |
| BRUGEL, H | 1 |
| MERTZ, DP | 1 |
| ALLODI, A | 1 |
| MURATORI, F | 1 |
| Cho, YK | 1 |
| Kim, BI | 1 |
| Maier, KP | 1 |
| Kearney, BP | 1 |
| Yale, K | 1 |
| Shah, J | 1 |
| Zhong, L | 1 |
| Flaherty, JF | 1 |
| Gutiérrez, S | 1 |
| Guillemi, S | 1 |
| Jahnke, N | 1 |
| Montessori, V | 1 |
| Harrigan, PR | 1 |
| Montaner, JS | 1 |
| Malins, DC | 1 |
| Polissar, NL | 1 |
| Garner, MM | 1 |
| Gunselman, SJ | 1 |
| Teckman, JH | 1 |
| Perlmutter, DH | 1 |
| Molnar, JJ | 1 |
| Riede, UN | 1 |
| Widmer, A | 1 |
| Rohr, HP | 1 |
| Heirwegh, KP | 1 |
| Ramboer, C | 1 |
| De Groote, J | 1 |
| Piazza, E | 1 |
| Sindoni, G | 1 |
| Stornello, C | 1 |
| Foti, V | 1 |
| Chlumský, J | 1 |
| Hyncík, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment[NCT01767948] | Phase 1 | 30 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for adenine and Liver Dysfunction
| Article | Year |
|---|---|
[Tenofovir: pharmacology and interactions].
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug | 2008 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease | 2012 |
[Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Liver Diseases; Organophosphonates | 2003 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Scleros | 2005 |
3 trials available for adenine and Liver Dysfunction
| Article | Year |
|---|---|
Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.
Topics: Adenine; Adult; Antiviral Agents; B-Lymphocytes; Female; Flow Cytometry; Hepatitis B, Chronic; Homeo | 2013 |
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment.
Topics: Adenine; Adult; Aged; Area Under Curve; Biomarkers; Drug Monitoring; Female; Humans; Incidence; Live | 2017 |
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Topics: Adenine; Adult; Aged; Drug Administration Schedule; Drug Monitoring; Female; Humans; Liver Diseases; | 2006 |
17 other studies available for adenine and Liver Dysfunction
| Article | Year |
|---|---|
25-Hydroxycholesterol mitigates hepatic ischemia reperfusion injury via mediating mitophagy.
Topics: Adenine; Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Disease Models, Anim | 2021 |
Adenine base editing and prime editing of chemically derived hepatic progenitors rescue genetic liver disease.
Topics: Adenine; Animals; Gene Editing; Hepatocytes; Liver Diseases; Mice | 2021 |
Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bile Acids and Salts; Blood Chemical Analysis; Calibra | 2015 |
The Dichotomy of Endoplasmic Reticulum Stress Response in Liver Ischemia-Reperfusion Injury.
Topics: Activating Transcription Factors; Adenine; AMP-Activated Protein Kinases; Animals; Autophagy; Autoph | 2016 |
[Conclusions. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Hu | 2008 |
Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population.
Topics: Adenine; Adult; Age Distribution; Aged; Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; Cytochro | 2009 |
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.
Topics: Adenine; Animals; Apoptosis; Cyclin-Dependent Kinases; Disease Models, Animal; Humans; Kidney Diseas | 2012 |
[Treatment of diseases of liver parenchyma; experiences with intravenous injections of a preparation containing a mixture of orotic acid and purines].
Topics: Adenine; Humans; Injections, Intravenous; Liver Diseases; Orotic Acid; Purines; Xanthines | 1956 |
[Effects of a new preparation of purinic and orotic acid base in chronic liver diseases].
Topics: Adenine; Alkalies; Humans; Liver Diseases; Organic Chemicals; Orotic Acid; Xanthines | 1957 |
Labeling changes for tenofovir.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Interactions; Drug Labeling; Drug Therapy, Combination | 2004 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepa | 2008 |
Mutagenic DNA base modifications are correlated with lesions in nonneoplastic hepatic tissue of the English sole carcinogenesis model.
Topics: Adenine; Age Factors; Animals; Confounding Factors, Epidemiologic; Fish Diseases; Guanine; Liver Dis | 1996 |
Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response.
Topics: Adenine; alpha 1-Antitrypsin; Animals; Autophagy; CHO Cells; Cricetinae; Endoplasmic Reticulum; Fibr | 2000 |
[Adenine induced liver parenchymal cell injury].
Topics: Adenine; Animals; Chemical and Drug Induced Liver Injury; Liver; Liver Diseases; Male; Microscopy, E | 1970 |
Purine and pyrimidine excretion. I. Chromatographic separation and identification of purine and pyrimidine metabolites in human urine.
Topics: Adenine; Chromatography; Chromatography, Paper; Creatine; Diet; Humans; Hypoxanthines; Liver Disease | 1967 |
[Clinico-therapeutic evaluation of a new drug combination with hepatotrophic effect].
Topics: Adenine; Adult; Child; Drug Combinations; Folic Acid; Hepatitis A; Humans; Hydroxocobalamin; Inosine | 1972 |
[Problem of active therapeutic procedure in chronic liver disease].
Topics: Adenine; Adult; Aged; Chronic Disease; Diet Therapy; Female; Humans; Inositol; Liver Diseases; Male; | 1972 |